Sanofi has announced an agreement to acquire Dynavax Technologies Corporation, a publicly listed vaccines company best known for its marketed adult hepatitis B vaccine, HEPLISAV-B, and a differentiated shingles vaccine candidate.
The acquisition strengthens Sanofi’s position in adult immunization by combining Dynavax’s vaccine portfolio with Sanofi’s global development expertise, manufacturing capabilities and commercial scale.
HEPLISAV-B, currently marketed in the United States, is distinguished by its two-dose schedule administered over one month. This regimen allows for faster and higher levels of seroprotection compared with traditional hepatitis B vaccines, which typically require three doses over a six-month period.
As part of the transaction, Sanofi will also acquire Dynavax’s shingles vaccine candidate, Z-1018, which is in phase 1/2 clinical development, along with additional vaccine pipeline assets. The deal further expands Sanofi’s vaccines portfolio and supports its long-term strategy to advance innovative solutions in adult and preventive healthcare.
Click here to join our WhatsApp channel here
“Dynavax enhances Sanofi’s adult immunization presence by adding differentiated vaccines that complement Sanofi’s expertise,” said Thomas Triomphe, Executive Vice President, Vaccines, Sanofi. “Its marketed adult hepatitis B vaccine and shingles candidate bring new options to our portfolio and underscore our commitment to providing vaccine protection across the lifespan.”
“Joining Sanofi will provide the global scale and expertise needed to maximize the impact of our vaccine portfolio,” said Ryan Spencer, Chief Executive Officer, Dynavax. “We believe Sanofi’s commercial reach, development capabilities, and commitment to evidence-based immunization will amplify the opportunity for HEPLISAV-B and our innovative pipeline to address important public health needs, further advancing our mission to help protect the world against infectious disease. We are confident that this transaction and the compelling value it provides is in the best interests of the Company and its stockholders.”
